Humacyte (HUMA) Treasury Shares (2020 - 2021)

Humacyte (HUMA) posted quarterly Treasury Shares of $69.6 million for Q2 2021, little changed quarter-over-quarter from $69.6 million in Q1 2021.

Humacyte (HUMA) Treasury Shares (2020 - 2021) Analysis & Trends

Humacyte (HUMA) has reported Treasury Shares for 2 consecutive years, with $69.6 million the latest figure, recorded in Q2 2021.

In Q2 2021, Treasury Shares changed N/A year-over-year to $69.6 million; the TTM figure through Jun 2021 stood at $69.6 million (changed N/A YoY), while the FY2020 annual figure was $69.6 million, changed N/A from the prior year.
Treasury Shares was little changed at $69.6 million in Q2 2021 per HUMA's latest filing, from $69.6 million in the prior quarter.
Across five years, Treasury Shares topped out at $69.6 million in Q3 2020 and bottomed at $69.6 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	2.72 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	8.96 Mn
10	Humacyte	158.12 Mn	158.12 Mn	-825,000.00	-

Download Data